Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in Parkinson's Disease Psychosis
NCT06068465Phase 3Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
A Phase 3 trial of pimavanserin in Parkinson's disease (PD), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Sep 2023; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06068465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068465.